Wescott Financial Advisory Group LLC Acquires 7,522 Shares of Pfizer Inc. (NYSE:PFE)

Wescott Financial Advisory Group LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 94.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,517 shares of the biopharmaceutical company’s stock after buying an additional 7,522 shares during the quarter. Wescott Financial Advisory Group LLC’s holdings in Pfizer were worth $449,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in Pfizer during the 1st quarter worth about $315,000. Bellevue Group AG raised its holdings in Pfizer by 48.0% during the 1st quarter. Bellevue Group AG now owns 33,834 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 10,966 shares during the last quarter. Mount Yale Investment Advisors LLC raised its holdings in Pfizer by 25.7% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 22,128 shares of the biopharmaceutical company’s stock worth $614,000 after purchasing an additional 4,525 shares during the last quarter. Lavaca Capital LLC grew its position in shares of Pfizer by 5.6% during the 1st quarter. Lavaca Capital LLC now owns 11,248 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 601 shares during the period. Finally, Waverly Advisors LLC grew its position in shares of Pfizer by 36.3% during the 1st quarter. Waverly Advisors LLC now owns 165,821 shares of the biopharmaceutical company’s stock worth $4,602,000 after buying an additional 44,118 shares during the period. 68.36% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Trading Up 2.1 %

NYSE:PFE opened at $25.65 on Friday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $28.21 and a two-hundred day moving average price of $28.57. The company has a market cap of $145.36 billion, a P/E ratio of 34.66, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the firm posted ($0.17) EPS. The business’s revenue was up 31.2% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.